Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Recommendation of “Moderate Buy” by Analysts

Oncolytics Biotech Inc. (NASDAQ:ONCY) has received an average rating of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $5.00.

ONCY has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Wednesday, October 8th. Lake Street Capital assumed coverage on Oncolytics Biotech in a report on Wednesday, August 13th. They issued a “buy” rating and a $7.00 price objective for the company. Zacks Research raised Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Finally, Wall Street Zen upgraded shares of Oncolytics Biotech from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th.

Oncolytics Biotech Stock Down 4.8%

NASDAQ:ONCY opened at $1.08 on Friday. The company’s 50 day moving average price is $1.22 and its 200-day moving average price is $0.94. Oncolytics Biotech has a 52 week low of $0.33 and a 52 week high of $1.51. The stock has a market cap of $108.39 million, a price-to-earnings ratio of -4.00 and a beta of 1.32.

Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. As a group, sell-side analysts anticipate that Oncolytics Biotech will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On Oncolytics Biotech

A hedge fund recently raised its stake in Oncolytics Biotech stock. Seeds Investor LLC boosted its stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) by 17.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 223,767 shares of the company’s stock after purchasing an additional 33,826 shares during the period. Seeds Investor LLC owned approximately 0.23% of Oncolytics Biotech worth $173,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.